ArticleScientific reports2025
Clinical utility of NTproBNP as a fluid assessment and prognostic tool in PD patients.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The N-terminal pro-brain natriuretic peptide (NTproBNP) is a proven biomarker of myocardial structure/function and fluid volume status in the general population and prognostic marker of survival in cardiac failure patients. However, its utility for ESRD patients on peritoneal dialysis (PD) is under-studied. Our study aimed to evaluate the correlation of NTproBNP level with various biochemical parameters, fluid status and heart function in PD patients. Also, to determine the cutoff of NTproBNP level in predicting hypervolemic state. This is a cross-sectional study of stable peritoneal dialysis patients in the University of Malaya. Consented patients will be subjected to biochemical, echocardiogram, and bio-impedance analysis. Hypervolemic state is defined by an extracellular water/total body water (ECW/TBW) ratio of ≥ 0.40. NTproBNP level was taken at the same setting. 77 patients were recruited with male to female of 61% (n = 47) and 39% (n = 30). 33 patients (42.9%) were found to have over-hydration. There was a positive correlation between logNTproBNP with logECW/TBW ratio (r = 0.60, p = < 0.01). The performance of NTproBNP as a screening tool for over-hydration yielded an area under the ROC curve (AUC) of 0.80 (CI 95%; 0.701-0.898; P = < 0.001), and a threshold value of 2305 pg/ml has a sensitivity of 90%, specificity of 62%. The mortality rate at short-term follow-up was statistically higher in the high NTproBNP cohort (0% vs 17.9%; p = 0.027). Our study confirmed that NTproBNP correlates with hydration status in the PD cohort. It's useful in predicting clinical phenotypes and potentially a prognostic marker for patient survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.